Nature Communications (Apr 2017)
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
- Haikuo Zhang,
- Christine Fillmore Brainson,
- Shohei Koyama,
- Amanda J. Redig,
- Ting Chen,
- Shuai Li,
- Manav Gupta,
- Carolina Garcia-de-Alba,
- Margherita Paschini,
- Grit S. Herter-Sprie,
- Gang Lu,
- Xin Zhang,
- Bryan P. Marsh,
- Stephanie J. Tuminello,
- Chunxiao Xu,
- Zhao Chen,
- Xiaoen Wang,
- Esra A. Akbay,
- Mei Zheng,
- Sangeetha Palakurthi,
- Lynette M. Sholl,
- Anil K. Rustgi,
- David J. Kwiatkowski,
- J Alan Diehl,
- Adam J. Bass,
- Norman E. Sharpless,
- Glenn Dranoff,
- Peter S. Hammerman,
- Hongbin Ji,
- Nabeel Bardeesy,
- Dieter Saur,
- Hideo Watanabe,
- Carla F. Kim,
- Kwok-Kin Wong
Affiliations
- Haikuo Zhang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Christine Fillmore Brainson
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Shohei Koyama
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Amanda J. Redig
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ting Chen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Shuai Li
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Manav Gupta
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Carolina Garcia-de-Alba
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Margherita Paschini
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Grit S. Herter-Sprie
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Gang Lu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xin Zhang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Bryan P. Marsh
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Stephanie J. Tuminello
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Chunxiao Xu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Zhao Chen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xiaoen Wang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Esra A. Akbay
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Mei Zheng
- Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School
- Sangeetha Palakurthi
- Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
- Lynette M. Sholl
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Anil K. Rustgi
- Division of Gastroenterology, Department of Medicine and Genetics, University of Pennsylvania Perelman School of Medicine, Abramson Cancer Center
- David J. Kwiatkowski
- Department of Medical Oncology, Dana-Farber Cancer Institute
- J Alan Diehl
- Department of Biochemical and Molecular Biology, Medical University of South Carolina
- Adam J. Bass
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Norman E. Sharpless
- University of North Carolina Lineberger Comprehensive Cancer Center, UNC School of Medicine
- Glenn Dranoff
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Peter S. Hammerman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Hongbin Ji
- Key Laboratory of Systems Biology, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Nabeel Bardeesy
- Cancer Center, Massachusetts General Hospital
- Dieter Saur
- Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München
- Hideo Watanabe
- Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
- Carla F. Kim
- Stem Cell Program and Division of Hematology/Oncology, Boston Children’s Hospital Boston
- Kwok-Kin Wong
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/ncomms14922
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
The mechanisms that govern the transdifferentiation of lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) are not fully understood. Here, the authors show that EZH2 loss exacerbates the transdifferentiation of ADCs to SCCs as a result of chromatin changes that lead to expression of squamous differentiation genes.
